Denise Damek

811 total citations
19 papers, 411 citations indexed

About

Denise Damek is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Denise Damek has authored 19 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Neurology. Recurrent topics in Denise Damek's work include Glioma Diagnosis and Treatment (14 papers), Brain Metastases and Treatment (6 papers) and Meningioma and schwannoma management (5 papers). Denise Damek is often cited by papers focused on Glioma Diagnosis and Treatment (14 papers), Brain Metastases and Treatment (6 papers) and Meningioma and schwannoma management (5 papers). Denise Damek collaborates with scholars based in United States. Denise Damek's co-authors include Fred H. Hochberg, Craig Evan Pollack, Nandita Guha‐Thakurta, Kevin O. Lillehei, Brian D. Kavanagh, Laurie E. Gaspar, Changhu Chen, Douglas Ney, Bette K. Kleinschmidt‐DeMasters and Kelly Stuhr and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Denise Damek

17 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Denise Damek United States	9	328	176	143	105	67	19	411
A. Monjour France	7	373 1.1×	210 1.2×	181 1.3×	155 1.5×	67 1.0×	10	449
Ina Ly United States	9	171 0.5×	178 1.0×	77 0.5×	53 0.5×	70 1.0×	28	421
Mary Welch United States	12	237 0.7×	124 0.7×	92 0.6×	95 0.9×	27 0.4×	37	405
Antonino Rotilio Italy	12	344 1.0×	153 0.9×	167 1.2×	33 0.3×	148 2.2×	18	562
Cheng‐Ying Shiau Taiwan	15	211 0.6×	168 1.0×	232 1.6×	95 0.9×	143 2.1×	29	616
Lee McNeely United States	9	119 0.4×	196 1.1×	130 0.9×	114 1.1×	107 1.6×	12	380
Vincent Cheung United States	7	343 1.0×	101 0.6×	131 0.9×	44 0.4×	127 1.9×	13	510
Lillian Tseng United States	12	189 0.6×	219 1.2×	67 0.5×	37 0.4×	53 0.8×	22	474
Atmaram S. Pai Panandiker United States	13	220 0.7×	216 1.2×	101 0.7×	35 0.3×	76 1.1×	20	432
Kimberly R. Porter United States	6	176 0.5×	123 0.7×	97 0.7×	30 0.3×	94 1.4×	8	345

Countries citing papers authored by Denise Damek

Since Specialization

Citations

This map shows the geographic impact of Denise Damek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Damek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Damek more than expected).

Fields of papers citing papers by Denise Damek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Damek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Damek. The network helps show where Denise Damek may publish in the future.

Co-authorship network of co-authors of Denise Damek

This figure shows the co-authorship network connecting the top 25 collaborators of Denise Damek. A scholar is included among the top collaborators of Denise Damek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise Damek. Denise Damek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Ung, Timothy H., et al.. (2022). Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. BMC Cancer. 22(1). 367–367. 8 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2022). 280O Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results. Annals of Oncology. 33. S667–S667. 3 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2022). CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM). Neuro-Oncology. 24(Supplement_7). vii76–vii77. 1 indexed citations

Wen, Patrick Y., John Frederick De Groot, James Battiste, et al.. (2022). Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.. Journal of Clinical Oncology. 40(16_suppl). 2047–2047. 19 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2021). Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. Cancer Research. 81(13_Supplement). LB125–LB125. 3 indexed citations

Tatman, Philip D., Denise Damek, Kevin O. Lillehei, et al.. (2021). High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. Journal of Clinical Medicine. 10(14). 3150–3150. 6 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2020). CTNI-44. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/mTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER. Neuro-Oncology. 22(Supplement_2). ii52–ii52. 3 indexed citations

Ung, Timothy H., Douglas Ney, Denise Damek, et al.. (2018). The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma. Neurosurgery. 84(3). 687–695. 12 indexed citations

Trusheim, John, Erin Dunbar, James Battiste, et al.. (2016). A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncology. 6(1). 29–43. 35 indexed citations

10.

Carlson, Julie A., Krishna Reddy, Laurie E. Gaspar, et al.. (2015). Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Journal of Neuro-Oncology. 123(2). 251–257. 27 indexed citations

11.

Carlson, Joseph W., Krishna Reddy, Laurie E. Gaspar, et al.. (2014). Hypofractionated–Intensity Modulated Radiation Therapy (Hypo-IMRT) and Temozolomide (TMZ) With and Without Bevacizumab (BEV) for Glioblastoma Multiforme (GBM): A Comparison of 2 Prospective Phase 2 Trials. International Journal of Radiation Oncology*Biology*Physics. 90(1). S284–S284. 1 indexed citations

12.

Poonia, Seerat, Eamon M. Berge, Dara L. Aisner, Denise Damek, & Robert C. Doebele. (2014). EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy. Clinical Lung Cancer. 15(5). 387–389. 6 indexed citations

13.

Kleinschmidt‐DeMasters, Bette K., et al.. (2012). Anaplastic PXA in adults: case series with clinicopathologic and molecular features. Journal of Neuro-Oncology. 111(1). 59–69. 40 indexed citations

14.

Reddy, Krishna, Denise Damek, Laurie E. Gaspar, et al.. (2012). Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 84(3). 655–660. 59 indexed citations

15.

Reddy, Krishna, Denise Damek, Laurie E. Gaspar, et al.. (2011). Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 81(2). S130–S130. 1 indexed citations

16.

Chen, Changhu, Denise Damek, Laurie E. Gaspar, et al.. (2010). Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 81(4). 1066–1074. 44 indexed citations

17.

Baehring, Joachim M., Denise Damek, Emily C. Martin, Rebecca A. Betensky, & Fred H. Hochberg. (2003). Neurolymphomatosis. Neuro-Oncology. 5(2). 104–115. 6 indexed citations

18.

Guha‐Thakurta, Nandita, Denise Damek, Craig Evan Pollack, & Fred H. Hochberg. (1999). Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of Patients. Journal of Neuro-Oncology. 43(3). 259–268. 123 indexed citations

19.

McCarthy, Bridget J., Faith B. Davis, Sally Freels, et al.. (1997). Factors associated with survival in patients with meningioma. Neurosurgical FOCUS. 2(4). E3–E3. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact